Tag: Biocon

April 29, 2020 Off

Mylan, Biocon launch Fulphila in Canada

By Dino Mustafić

Mylan and Biocon have launched Fulphila, a biosimilar to Neulasta (pegfilgrastim), as it was approved by Health Canada to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.